Study to Evaluate D-1553 in Subjects With Solid Tumors
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.
Solid Tumor, Adult|NSCLC|CRC
DRUG: D-1553|DRUG: D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDAÂ® , Drug: cetuximab, Drug: other
Subject incidence of Dose-limiting toxicities (DLT), through out the DLT period, approximately 21 days|Number of subjects participants with adverse events, Through study completion, approximately 3 years|Plasma concentration of D-1553 as a single agent or in combination with other therapies in subjects wiht advanced or metastatic solid tumors with KRas G12C mutation., Through study completion, approximately 3 years
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.